<SEC-DOCUMENT>0001213900-25-022284.txt : 20250310
<SEC-HEADER>0001213900-25-022284.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310170003
ACCESSION NUMBER:		0001213900-25-022284
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250310
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Polyrizon Ltd.
		CENTRAL INDEX KEY:			0001893645
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42375
		FILM NUMBER:		25724612

	BUSINESS ADDRESS:	
		STREET 1:		12/6 BOROCHOV ST.
		CITY:			RAANANA
		STATE:			IL
		ZIP:			4343306
		BUSINESS PHONE:		972-54-7979668

	MAIL ADDRESS:	
		STREET 1:		12/6 BOROCHOV ST.
		CITY:			RAANANA
		STATE:			IL
		ZIP:			4343306
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0233751-6k_polyrizon.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form 6-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 207.1pt 0pt 208.2pt; text-align: center; text-indent: -0.05pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.05pt">Report of Foreign Private
Issuer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.05pt">Pursuant to Rule 13a-16 or
15d-16</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 190.65pt 0pt 191.75pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of March 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-42375</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>Polyrizon Ltd.</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&#8217;s name into English)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>5 Ha-Tidhar Street</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Raanana, 4366507, Israel</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<font style="font-family: Times New Roman, Times, Serif">&#9746;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;<font style="font-family: Times New Roman, Times, Serif">&#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>CONTENTS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attached hereto and incorporated herein is the
Registrant&#8217;s press release issued on March 10, 2025, titled &#8220;Polyrizon Initiates Preclinical Studies for Intranasal Naloxone
Targeting Opioid Overdose Based on Its Innovative T&amp;T Platform.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first, second, third, fifth and sixth paragraphs
of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant&#8217;s Registration
Statement on&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1893645/000121390025005494/ea0228158-s8_polyrizon.htm">Form S-8</a>&nbsp;(File
No. 333-284410), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Exhibit</b>&nbsp;<b>No.</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 90%; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">99.1</font></td>
    <td>&nbsp;</td>
    <td style="text-align: justify"><a href="ea023375102ex99-1_poly.htm"><font style="font-size: 10pt">Press release titled: &#8220;Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&amp;T Platform&#8221;</font></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95pt; text-align: center"><b><u>SIGNATURES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><b>Polyrizon Ltd.</b></font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><font style="font-size: 10pt">Date: March 10, 2025</font></td>
    <td style="width: 5%"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%"><font style="font-size: 10pt">/s/ Tomer Izraeli</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Name:&nbsp;</font></td>
    <td><font style="font-size: 10pt">Tomer Izraeli</font></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Title:</font></td>
    <td><font style="font-size: 10pt">Chief Executive Officer</font></td></tr>
  </table>
<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&nbsp;</b></p>
<p style="text-align: center; margin-top: 0; margin-bottom: 0">2</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023375102ex99-1_poly.htm
<DESCRIPTION>PRESS RELEASE TITLED: "POLYRIZON INITIATES PRECLINICAL STUDIES FOR INTRANASAL NALOXONE TARGETING OPIOID OVERDOSE BASED ON ITS INNOVATIVE T&T PLATFORM"
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; margin: 0"><b>Exhibit 99.1</b></p>

<p style="margin: 0">&nbsp;</p>

<p style="text-align: justify; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">Polyrizon
Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&amp;T Platform</font></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
(Nasdaq: PLRZ) (the &#8220;Company&#8221; or &#8220;Polyrizon&#8221;), a development stage biotech company specializing in the development
of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid
overdose treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The study will be conducted in collaboration with Professor Fabio Sonvico,
Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal
and pulmonary drug delivery solutions and a member of the Company&#8217;s Scientific Advisory Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These preclinical studies mark a step forward in evaluating Polyrizon&#8217;s
Trap and Target&trade; (T&amp;T) platform for the intranasal administration of Naloxone, an opioid antagonist designed to rapidly reverse
opioid overdose. These studies will assess key parameters, such as drug loading capacity, release kinetics, nasal deposition and stability,
laying the groundwork for further safety and efficacy testing in preclinical and clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;The opioid crisis continues to be a global
public health emergency and improving Naloxone administration is essential for saving lives,&#8221; said Tomer Izraeli CEO of Polyrizon.
&#8220;Our proprietary T&amp;T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal
Naloxone by offering higher bioavailability for increased drug effectiveness and optimized drug release profiles that ensure rapid opioid
reversal when every second counts. These advantages could make a critical difference in emergency overdose situations, providing a safer
and more accessible solution for at-risk individuals and first responders.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ongoing opioid epidemic, largely driven by
fentanyl and other synthetic opioids, has led to a dramatic rise in overdose fatalities worldwide. Naloxone, an FDA-approved opioid antagonist,
has been shown to reverse opioid toxicity when administered promptly after respiratory depression occurs.&nbsp;The
global Naloxone market&nbsp;is projected to reach $2.47 billion by 2032, growing at a CAGR of 11%.&nbsp;The
Naloxone intranasal spray market&nbsp;alone is expected to reach $1.4 billion by 2030 (Vantage Market Research, February 2022).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intranasal delivery of Naloxone presents several advantages, including
ease of administration, eliminating the need for trained medical personnel, reduced risk of needlestick injuries and increased accessibility,
allowing emergency responders, caregivers, and at-risk individuals to carry and use it effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>About Polyrizon</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Polyrizon is a development stage biotech company
specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based
shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial
tissue. Polyrizon&#8217;s proprietary Capture and Contain&nbsp;TM, or C&amp;C, hydrogel technology, comprised of a mixture of naturally
occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a &#8220;biological mask&#8221; with
a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&amp;C hydrogel technology
such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its
additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical
ingredients, or APIs, as Trap and Target &trade;, or T&amp;T. For more information, please visit&nbsp;https://polyrizon-biotech.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &#8220;forward-looking statements&#8221;
within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as &#8220;expects,&#8221;
&#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221;
and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using
forward-looking statements when it discusses its belief that its Trap and Target&trade; (T&amp;T) platform holds the potential to enhance
intranasal Naloxone by offering higher bioavailability for increased drug effectiveness and optimized drug release profiles that ensure
rapid opioid reversal. Forward-looking statements are not historical facts, and are based upon management&#8217;s current expectations,
beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed
in good faith. However, there can be no assurance that management&#8217;s expectations, beliefs and projections will be achieved, and
actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements
are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the
forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to
the Company&#8217;s reports filed from time to time with the Securities and Exchange Commission (&#8220;SEC&#8221;), including, but not
limited to, the risks detailed in the Company&#8217;s prospectus (Registration No. 333-266745), dated October 24, 2024 and filed with
the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking
statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting
forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking
statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not
incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michal Efraty</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IR@polyrizon-biotech.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>
<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
